Efficacy and Safety of Long-Term Administration of Esomeprazole in Japanese Pediatric Patients Aged 1–14 Years with Chronic Gastric Acid-Related Disease
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To evaluate prolonged esomeprazole use in Japanese pediatric patients for reflux esophagitis (RE) maintenance therapy and prevention of gastric (GU) and/or duodenal ulcers (DU) while using non-steroidal anti-inflammatory drugs (NSAIDs) or low-dose aspirin (LDA). Methods: This multicenter, open-label, parallel-group, phase III study (NCT03553563) included patients who were administered esomeprazole according to body weight (10 mg/day [Groups 1 and 3] and up to 20 mg/day [Groups 2 and 4] for patients weighing 10–20 kg and ≥20 kg, respectively). Efficacy outcomes for Groups 1 and 2 (maintenance therapy for healed RE) and Groups 3 and 4 (prevention of long-term NSAID/LDA use-associated GU/DU) were the presence/absence of RE relapse and GU/DU recurrence, respectively. Results: Esomeprazole as maintenance therapy was associated with a low RE recurrence rate, independent of body weight or dosage. Recurrence rates of RE were 0.0% and 5.3% for Groups 1 and 2, respectively. In patients previously diagnosed with GU and/or DU due to long-term NSAID/LDA use, the recurrence rates of GU/DU during weeks 0–32 were 11.1% and 0.0% in Groups 3 and 4, respectively. Conclusion: Long-term use of 10- or 20-mg, once-daily esomeprazole demonstrated a favorable benefit-risk balance in preventing RE and suppressing recurrence of GU and/or DU secondary to NSAID or LDA therapy in Japanese pediatric patients. No new safety concerns were identified. Esomeprazole may be a viable option for managing RE and preventing GU and DU in Japanese pediatric patients.
Abstract
Purpose: To evaluate prolonged esomeprazole use in Japanese pediatric patients for reflux esophagitis (RE) maintenance therapy and prevention of gastric (GU) and/or duodenal ulcers (DU) while using non-steroidal anti-inflammatory drugs (NSAIDs) or low-dose aspirin (LDA). Methods: This multicenter, open-label, parallel-group, phase III study (NCT03553563) included patients who were administered esomeprazole according to body weight (10 mg/day [Groups 1 and 3] and up to 20 mg/day [Groups 2 and 4] for patients weighing 10–20 kg and ≥20 kg, respectively). Efficacy outcomes for Groups 1 and 2 (maintenance therapy for healed RE) and Groups 3 and 4 (prevention of long-term NSAID/LDA use-associated GU/DU) were the presence/absence of RE relapse and GU/DU recurrence, respectively. Results: Esomeprazole as maintenance therapy was associated with a low RE recurrence rate, independent of body weight or dosage. Recurrence rates of RE were 0.0% and 5.3% for Groups 1 and 2, respectively. In patients previously diagnosed with GU and/or DU due to long-term NSAID/LDA use, the recurrence rates of GU/DU during weeks 0–32 were 11.1% and 0.0% in Groups 3 and 4, respectively. Conclusion: Long-term use of 10- or 20-mg, once-daily esomeprazole demonstrated a favorable benefit-risk balance in preventing RE and suppressing recurrence of GU and/or DU secondary to NSAID or LDA therapy in Japanese pediatric patients. No new safety concerns were identified. Esomeprazole may be a viable option for managing RE and preventing GU and DU in Japanese pediatric patients.
참고문헌 (15)
- Mejia A, "Acid peptic diseases : pharmacological approach to treatment", Expert Rev Clin Pharmacol, 2, pp.295~314 (2009)
- Yamamichi N, "Inverse time trends of peptic ulcer and reflux esophagitis show significant association with reduced prevalence of Helicobacter pylori infection", Ann Med, 52, pp.506~514 (2020)
- Kusakari M, "Trends in gastroesophageal reflux disease in Japanese children and adolescents", Pediatr Int, 62, pp.1269~1274 (2020)
- Kakiuchi T, "Low-dose aspirin-induced gastric mucosal injury after Fontan surgery in an adolescent", Clin Case Rep, 9, pp.2460~2464 (2021)
- "Pharmaceuticals and medical devices safety information" (2011)[URL]
- Shimizu T, "Oral esomeprazole in Japanese pediatric patients with gastric acid-related disease : safety, efficacy, and pharmacokinetics", Pediatr Int, 61, pp.87~95 (2019)
- Lundell LR, "Endoscopic assessment of oesophagitis : clinical and functional correlates and further validation of the Los Angeles classification", Gut, 45, pp.172~180 (1999)
- Alatas FS, "Association between pediatric gastroesophageal reflux disease symptom and quality of life questionnaire score, endoscopy and biopsy in children with clinical gastroesophageal reflux disease : a prospective study", Pediatr Gastroenterol Hepatol Nutr, 26, pp.173~180 (2023)
- Sugano K, "Safety and efficacy of long-term esomeprazole 20 mg in Japanese patients with a history of peptic ulcer receiving daily non-steroidal anti-inflammatory drugs", BMC Gastroenterol, 13, pp.54~ (2013)
- Sugano K, "Multinational, double-blind, randomised, placebo-controlled, prospective study of esomeprazole in the prevention of recurrent peptic ulcer in low-dose acetylsalicylic acid users : the LAVENDER study", Gut, 63, pp.1061~1068 (2014)
- Gilger MA, "Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease", J Pediatr Gastroenterol Nutr, 46, pp.524~533 (2008)
- Zhao J, "Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease : a randomized, open-label study", Clin Ther, 28, pp.1868~1876 (2006)
- Sugano K, "Randomised clinical trial : esomeprazole for the prevention of nonsteroidal anti-inflammatory drug-related peptic ulcers in Japanese patients", Aliment Pharmacol Ther, 36, pp.115~125 (2012)
- Kinoshita Y, "Efficacy and safety of esomeprazole, compared with omeprazole, in maintenance therapy for reflux esophagitis -a phase III, multicenter, randomized, double-blind trial-", Nihon Shokakibyo Gakkai Zasshi, 110, pp.1428~1438 (2013)
- Ohara S, "Nationwide epidemiological survey regarding heartburn and reflux esophagitis in Japanese", Nihon Shokakibyo Gakkai Zasshi, 102, pp.1010~1024 (2005)